Janssen Research & Development, Llc

This early-phase study tests an experimental drug called JNJ-87890387 in people with advanced solid tumors (kidney, ovarian, uterine, colorectal, or lung cancer) that have spread or cannot be removed. The main goals are to find a safe dose and check for side effects. About 200 pa…

This study tests a new drug called bleximenib for people with acute leukemia that has come back or not responded to other treatments. The drug targets specific genetic changes in the cancer cells. The study will first find the best dose and then check if it can safely help patien…

This early-stage study tests a new drug combination for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The treatment uses a T-cell redirecting agent (pasritamig) plus an A2a receptor blocker to help the immune system attack c…

This study tests a medicine called nipocalimab in pregnant women whose babies are at high risk for severe hemolytic disease (HDFN), a condition where the mother's immune system attacks the baby's red blood cells. The goal is to see if the drug can prevent serious problems like se…

This study tests two new drug combinations (Tal-P and Tal-Tec) against standard treatments for people with multiple myeloma that has returned or stopped responding after 1 to 4 prior therapies. About 795 participants will be randomly assigned to one of the combinations or standar…

This study tests a drug called amivantamab, alone or with standard chemotherapy, in people with advanced colorectal cancer that has spread. The goal is to see if the drug can shrink tumors and to find the safest dose when combined with chemo. About 225 adults whose cancer has not…

This study tests a new drug, JNJ-79635322, against another antibody treatment for people with multiple myeloma that has returned or stopped responding after at least three prior therapies. About 400 participants will be randomly assigned to one of the two treatments. The goal is …

This study tests a new drug called JNJ-88545223 in 240 adults with active psoriatic arthritis, a condition causing joint pain and skin patches. Participants will receive either the drug or a placebo to see if it improves joint swelling and skin symptoms. The goal is to find a bet…

This study compares two drug combinations as first treatment for people with a specific type of advanced colorectal cancer that cannot be removed by surgery or has spread. About 1000 adults will receive either amivantamab plus chemotherapy or cetuximab plus chemotherapy. The goal…

This study tests a new drug (JNJ-78278343) combined with other treatments for men whose prostate cancer has spread and no longer responds to hormone therapy. The goal is to find the safest and most effective dose and to monitor side effects. About 300 participants will be enrolle…

This study tests how well nipocalimab works compared to efgartigimod for people with generalized myasthenia gravis, a condition where the immune system attacks nerve-muscle connections, causing weakness. About 115 adults will receive one of the two drugs to see which better contr…

This early-stage study tests a combination of two experimental drugs for men with a type of advanced prostate cancer that no longer responds to hormone therapy. The first drug is designed to direct the body's immune T-cells to attack cancer cells, while the second delivers a toxi…

This early-stage study tests an experimental drug called JNJ-79635322, a trispecific antibody designed to attack cancer cells from multiple angles. It is for people with relapsed or refractory multiple myeloma or AL amyloidosis who have tried other treatments. The main goals are …

This study tests an investigational drug called JNJ-95597528 in 180 adults with moderate to severe atopic dermatitis (eczema). Participants receive either the drug or a placebo to see if it improves skin symptoms like redness, thickness, and itching. The main goal is to measure a…

This early-stage study tests an experimental drug called JNJ-88549968 in people with certain blood cancers (myelofibrosis or essential thrombocythemia) that have a specific CALR gene mutation. The drug is a bispecific antibody designed to redirect the body's immune T-cells to att…

This early-stage study tests a new drug called JNJ-95437446 in about 380 adults with advanced solid tumors, including colorectal, lung, and head/neck cancers that have not responded to other treatments. The main goals are to find the safest dose and check for side effects. Resear…

This study tests whether adding the drug amivantamab to standard chemotherapy and immunotherapy can help people with advanced head and neck cancer live longer. About 500 adults who have not had prior treatment for their recurrent or metastatic cancer will take part. The goal is t…

This early-phase study is testing a new experimental drug called JNJ-95566692, a trispecific antibody designed to attach to three different targets on lymphoma cells and immune cells to help the body fight the cancer. The study includes about 130 adults with B-cell non-Hodgkin ly…

This study tests whether a new drug called amivantamab, combined with standard chemotherapy (FOLFIRI), helps people with a certain type of advanced colorectal cancer live longer without their disease getting worse. It is for patients whose cancer has returned or spread and who ha…

This early-phase study tests a new drug (JNJ-79635322) combined with standard treatments for multiple myeloma, a blood cancer. About 140 participants will receive different drug combinations to find the safest and most effective dose. The goal is to control the disease, not cure …

This study tests a combination of two drugs, amivantamab and olomorasib, in people with a specific type of advanced lung cancer (KRAS G12C mutation) that has spread. The goal is to find the best dose and see if the combo can shrink tumors or slow their growth. About 60 participan…

This study tests a new drug called pasritamig, which helps the body's immune cells attack prostate cancer cells. It is for people with advanced prostate cancer that has spread and no longer responds to hormone therapy. About 663 participants will receive either pasritamig plus be…

This study tests a new drug called talquetamab for people with multiple myeloma, a type of blood cancer, that has returned or not responded to other treatments. The drug is designed to help the immune system attack cancer cells. About 510 participants will receive the drug to see…

This study is testing how well the drug guselkumab works for people with psoriatic arthritis (PsA), a condition that causes joint pain and swelling. Researchers will use ultrasound to measure joint inflammation in 200 adults over 24 weeks. The goal is to see if guselkumab reduces…

This study tests a drug called amivantamab, alone or with other cancer medicines, in people with head and neck cancer that has spread or come back. The goal is to see if these treatments can shrink tumors and are safe. About 287 adults will take part.

This study follows 150 people with early-stage bladder cancer (NMIBC) who are receiving TAR-200 treatment in everyday medical practice. Researchers want to see how long it takes for the cancer to come back or get worse after starting TAR-200. The goal is to understand how well th…

This study compares two medications, guselkumab and risankizumab, to see which is more effective at controlling moderate to severe Crohn's disease. About 530 adults with active Crohn's will receive one of the two drugs. The main goal is to see how many achieve deep remission—mean…

This study tests two drug combinations for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation). One group gets a new drug (amivantamab) plus a targeted pill (lazertinib) as their first treatment. Another group gets amivantamab with c…

This study tests whether adding the experimental drug bleximenib to standard medicines (venetoclax and azacitidine) helps people with a specific genetic subtype of acute myeloid leukemia (AML) achieve remission and live longer. It includes 600 adults aged 18 and older who are new…

This study tests a new medicine called nipocalimab against a standard treatment (IVIG) in 50 pregnant women whose babies are at risk for a rare condition that causes low platelets and severe bleeding. The goal is to see if nipocalimab can better prevent death or serious bleeding …

This study tests a subcutaneous (under-the-skin) form of the drug amivantamab in people with advanced EGFR-mutated non-small cell lung cancer. About 520 participants will receive the drug in different combinations to see if it shrinks tumors and how safe it is. The goal is to con…

This study tests an experimental pill, JNJ-77242113, in 750 adults with active psoriatic arthritis (PsA) who have tried other treatments. The goal is to see if it reduces joint pain, swelling, and skin symptoms better than a placebo. Participants will be monitored for 16 weeks to…

This study tests a drug called nipocalimab to see if it can prevent severe bleeding or death in unborn babies with a rare condition called FNAIT, where the mother's immune system attacks the baby's platelets. Pregnant women who have had a previous pregnancy affected by FNAIT are …

This study tests a drug called nipocalimab in adults with generalized myasthenia gravis, a condition that causes muscle weakness. About 199 participants will receive either the drug or a placebo to see if it improves daily activities like talking, chewing, and breathing. The goal…

This study tests a drug called guselkumab in 120 children with moderate to severe Crohn's disease. The goal is to see if it can reduce gut inflammation and improve symptoms over 52 weeks. Participants must have active disease confirmed by endoscopy. This is a phase 3 trial, meani…

This study tests a new treatment called TAR-210 for people with a high-risk type of bladder cancer that has a specific genetic change (FGFR alteration). Participants have already received standard BCG therapy. The study compares TAR-210 to standard chemotherapy placed directly in…

This study tests a drug called nipocalimab in children aged 2 to 18 with generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to see if the drug safely lowers harmful antibodies and improves daily activities. About 12 children will receive the drug,…

This study follows people who already received an eye injection of JNJ-81201887 or a sham in earlier trials for geographic atrophy, a form of advanced age-related macular degeneration. The goal is to check long-term safety by monitoring eye health and side effects over time. Abou…

This study tests a drug called bedaquiline, given together with other TB medicines, in children and teens (birth to under 18 years) who have multidrug-resistant tuberculosis (MDR-TB) of the lungs. The goal is to see how safe the drug is, how the body processes it, and whether it …

This study tests a drug called nipocalimab in adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder that causes weakness and numbness. The goal is to see if nipocalimab can delay or prevent relapses compared to a placebo. About 201 participants wi…

This study compares a new drug delivery system (TAR-210) to standard chemotherapy for people with a specific type of bladder cancer that hasn't invaded muscle. The treatment is placed directly into the bladder. About 641 participants will be randomly assigned to receive either TA…

This study tests a new way to deliver the drug erdafitinib directly into the bladder using a special system called TAR-210. It is for people with bladder cancer that has not spread into the muscle layer or has spread into it. The goal is to find the best dose and see if it is saf…

This study looks at different ways to give the drug ibrutinib to people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Some participants will also get another drug called venetoclax. The goal is to see if lowering the dose early or changing it based on…

This study tests whether nipocalimab can reduce lupus disease activity better than a placebo. About 600 adults with moderate to severe lupus will receive either the drug or a placebo for 52 weeks. The main goal is to see if more people on nipocalimab achieve a meaningful reductio…

This study is testing a new oral medication called icotrokinra for adults and adolescents with moderate-to-severe ulcerative colitis, a chronic inflammatory bowel disease. The main goal is to see if the drug can safely bring the disease into remission and keep it under control ov…

This study tests whether a nasal spray containing esketamine, given alongside standard care, can quickly reduce symptoms of major depression and suicidal thoughts in teenagers. About 258 adolescents with acute suicidal thoughts will receive either the active spray or a placebo th…

This study tests a drug called seltorexant for people with major depression who also have trouble sleeping and haven't gotten enough help from their current antidepressant. About 752 adults and elderly will take either seltorexant or a placebo pill alongside their usual antidepre…

This study tests whether seltorexant, a drug that targets sleep, can improve depressive symptoms in 600 adults with major depression and insomnia. Participants receive either the drug or a placebo for several weeks, then all may receive the drug long-term. The goal is to see if t…

This study tests if certain preventive treatments can reduce or prevent taste changes caused by a multiple myeloma drug called talquetamab. About 210 people with multiple myeloma will be randomly assigned to different preventive strategies. The goal is to improve quality of life …

This study tracks 380 people with a common type of advanced lung cancer (EGFR-mutated NSCLC) who are already receiving the approved drug amivantamab as part of their normal care. Researchers will collect information on how long patients stay on treatment and how well it controls …

This study aims to understand sleep patterns in people with major depressive disorder who have either moderate-to-severe insomnia or mild-to-no insomnia. About 80 participants will wear a headband at home that records brain activity during sleep, and also fill out sleep diaries a…

This study looks at how the body absorbs, breaks down, and gets rid of a radioactive form of the drug bleximenib in 10 people with acute leukemia. Participants have a type of leukemia that has come back or not responded to other treatments. The goal is to understand the drug's pa…

This study is a global registry that will follow about 175 pregnant people who are at risk for hemolytic disease of the fetus and newborn (HDFN), a condition where the mother's and baby's blood types don't match, causing the baby's red blood cells to break down too fast. Research…

This study follows about 295 people with multiple myeloma who have already received the cell therapy cilta-cel. The goal is to watch for delayed side effects, such as new cancers, nerve problems, or serious infections. No new treatment is given—participants are simply monitored o…